Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Free Report

White Paper_2017_State of China Life Science

State of China Life Science - 2017H1

Over $10B invested in last 18 months! Download free report on life science investment in China.

Cord Blood America Licenses Technology to AXM Pharma in China

publication date: Apr 6, 2010
Cord Blood America, Inc. has signed a deal licensing its umbilical cord blood technology to AXM Pharma, Inc., a China pharma and nutraceutical company. In addition to the license, Cord Blood America will provide consulting and training. In return, it will receive a 10% equity stake in AXM Pharma's stem cell subsidiary and an 8.5% royalty on all cord blood revenues. More details...

Stock Symbols: (OTCBB: CBAI) (OTCPK: AXMP)

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China